Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Ruxolitinib | 0.3 | uM | Leptin | 1 | ng/mL | 3 | IL-17 | 44.0 | 75 | |
N2586 | Tofacitinib | 0.3 | uM | Leptin | 1 | ng/mL | 3 | IL-17 | 48.5 | 84 | |
N2586 | IKK16 | 2.0 | uM | Leptin | 1 | ng/mL | 3 | IL-17 | 50.5 | 70 | |
RA2159 | Adiponectin | 5 | ng/mL | 3 | IL-17 | 45.0 | 72 | ||||
RA2159 | PD184352 | 0.1 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 46.5 | 84 | |
RA2159 | Lestaurtinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 45.0 | 78 | |
RA2159 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 53.0 | 62 | |
RA2159 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 44.0 | 64 | |
RA2159 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 49.0 | 69 | |
N2586 | Adiponectin | 5 | ng/mL | 3 | IL-17 | 48.0 | 73 | ||||
N2586 | PD184352 | 0.1 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 48.0 | 55 | |
N2586 | Lestaurtinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 46.0 | 66 | |
N2586 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 50.5 | 62 | |
N2586 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 47.0 | 59 | |
N2586 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | IL-17 | 47.0 | 63 | |
RA2159 | IGF-I | 100 | ug/mL | 3 | IL-17 | 48.0 | 72 | ||||
RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 47.0 | 67 | |
RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 44.0 | 72 | |
RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 45.0 | 69 | |
RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 45.0 | 77 | |
RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 48.5 | 68 | |
RA2159 | 3 | IL-17 | 50.0 | 62 | |||||||
N2586 | IGF-I | 100 | ug/mL | 3 | IL-17 | 49.0 | 63 | ||||
N2586 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 42.5 | 52 | |
N2586 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IL-17 | 42.0 | 74 |